Hormone-resistant prostate cancer with symptomatic pelvic tumours: Patient survival and prognostic factors

BJU International

Volumn 86, Issue 3, 2000, Pages 240-247

  Hernes, E H ^c   Linja, M ^b   Fossa S D ^a   Visakorpi, T ^b   Berner, A ^a   Winderen, M ^a   Koivisto, P A ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TAMPERE   (Finland)

^c Norwegian Radium Hospital ^*

Author keywords

Androgen receptors; Hormone resistant prostate cancer; Ki 67; p53; Pelvic tumour; Survival

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ESTROGEN; GONADORELIN; HORMONE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL FEATURE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; PELVIS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; SYMPTOM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PALLIATIVE CARE; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0033863612     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00767.x     Document Type: Article

References (28)

1. 1 Otnes B, Harvei S, Fossa SD. The burden of prostate cancer from diagnosis until death. Br J Urol 1995; 76: 587-94
2. 2 Taylor CD, Mson P. Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 2167-72
3. 3 Fossa SD, Dearnaley DP, Law M, Gad J, Newling DW, Tveter K. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 1992; 3: 361-6
4. 4 Fossa SD. Palliative pelvic radiotherapy in patients with hormone-resistant prostatic cancer. Prog Clin Biol Res 1987; 243B: 479-85
5. 5 Lankford SP, Pollack A, Zagars GK. Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 907-12
6. 6 Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9
7. 7 Tan J, Sharief Y, Hamil KG et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997; 11: 450-9
8. 8 Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995; 1: 1295-300
9. 9 Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostoli FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 1064-8
10. 10 Berner A, Nesland JM, Waehre H, Silde J. Fossa SD. Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre-and post-treatment specimens. Br J Cancer 1993; 68: 380-4
11. 11 Heidenberg HB, Sesterhenn IA. Gaddipati JP et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154: 414-21
12. 12 Cancer in Norway. The Cancer Registry of Norway, Institute of Epidemiological Cancer Research 1996
13. 13 Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumors. International classification of tumors. No. 22. World Health Organization 1980
14. 14 Sobin LH, Wittekind CH, eds. UICC TNM Classification of Malignant Tumours 5. New York: John Wiley & Sons, Inc. 1997
15. 15 Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202
16. 16 Osen I, Fossa SD, Majak B, Rotterud R, Berner A. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br J Urol 1998; 81: 862-9
17. 17 Skjorten FJ, Berner A, Harvei S, Robsahm TE, Tretli S. Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Cancer 1997; 79: 1172-9
18. 18 Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6
19. 19 Hyytinen E, Visakorpi T, Kallioniemi A, Kallioniemi OP, Isola JJ. Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry 1994; 16: 93-9
20. 20 Janssen PJ. Brinkmann AO, Boersma WJ, van-der-Kwast TH. Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histochem Cytochem 1994; 42: 1169-75
21. 21 Noordzij MA, van der Kwast TH, van Steenbrugge GJ, van Weerden WM, Oomen MH, Schroder FH. Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, paraffin-embedded prostatic cancer tissues. Prostate 1995; 27: 154-9
22. 22 Horne GM, Anderson JJ. Tiniakos DG et al. p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 1996; 73: 29-35
23. 23 Berner A, Geitvik G, Karlsen F, Fossa SD, Nesland JM. Borresen AL. TP53 mutations in prostatic cancer. Analysis of pre-and post-treatment archival formalin-fixed tumour tissue. J Pathol 1995; 176: 299-308
24. 24 Koivisto P, Visakorpi T, Rantala I, Isola J. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer.J Pathol 1997; 183: 51-6
25. 25 Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213-9
26. 26 Gregory CW, Hamil KG, Kim D et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998; 58: 5718-24
27. 27 Ogreid P, Berner A, Dahl O, Rettedal E, Fossa SD. Tissue prostate-specilic antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy. Eur Urol 1999; 36: 116-22
28. 28 Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991; 145: 802-6